A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer

  • S. Lindsey Davis
  • , Dana B. Cardin
  • , Safi Shahda
  • , Heinz Josef Lenz
  • , Efrat Dotan
  • , Bert H. O’Neil
  • , Ann M. Kapoun
  • , Robert J. Stagg
  • , Jordan Berlin
  • , Wells A. Messersmith
  • , Steven J. Cohen

Research output: Contribution to journal › Article › peer-review

83 Scopus citations

Fingerprint

Dive into the research topics of 'A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science